There is strong evidence for the use of the ketogenic diet (KD) in @entity3148 ( @entity3148 ). The purpose of this study was to evaluate both effectiveness and tolerability in comparison with various @entity734 ( @entity734 ). METHODS: 32 @entity1 (19 males) with genetically confirmed @entity3148 treated at our center since 1999 were analyzed retrospectively. Data collected from @entity1 ' files included type of mutation, age at treatment initiation and treatment lag, overall @entity410 frequency and frequency of different @entity410 types, especially prolonged @entity410 and @entity159 ( @entity159 ). Efficacy and safety of the KD were evaluated. In addition, the effect on @entity410 count was compared with that of various AED regimen and the vagus nerve stimulation (VNS). RESULTS: Overall response to the KD was 70% at 3 months and 60% at 12 months. No @entity159 occurred while @entity1 were on the diet, and the frequencies of prolonged generalized and @entity410 were reduced. No severe side effects requiring withdrawal of the KD were observed. Although the effect of the KD was independent of age at initiation, it had to be withdrawn due to noncompliance more frequently in solid fed older @entity1 compared with @entity1 treated with the liquid ketogenic formula. The KD was not significantly inferior to the current gold standard AED triple combination of @entity2808 + @entity1092 + @entity8925 (89%), @entity54382 (78%), @entity1092 alone (48%), @entity1771 (35%) and VNS (37%) and significantly more effective than @entity4677 (30%; p=0.037, Pearson's Chi-square). SIGNIFICANCE: These data suggest that the KD ranks among currently used @entity734 as an effective treatment for @entity410 in @entity3148 . According to our results (good effect on @entity159 and prolonged @entity410 , good tolerability, less compliance problems due to formula treatment) the KD should be considered as an early treatment option in @entity1 with @entity3148 .

Efficacy and tolerability of the ketogenic diet in XXXX - Comparison with various standard antiepileptic drug regimen.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'infants'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures', 'myoclonic seizures'] @entity4677 :: ('MESH:C026098', 'Chemical') :: ['Levetiracetam'] @entity8925 :: ('MESH:C012255', 'Chemical') :: ['Clobazam'] @entity54382 :: ('MESH:D001965', 'Chemical') :: ['Bromides'] @entity1092 :: ('MESH:D014635', 'Chemical') :: ['Valproate'] @entity2808 :: ('MESH:C021092', 'Chemical') :: ['Stiripentol'] @entity1771 :: ('MESH:C052342', 'Chemical') :: ['Topiramate'] @entity3148 :: ('MESH:D004831', 'Disease') :: ['Dravet syndrome', 'DS'] @entity734 :: ('MESH:D019966', 'Disease') :: ['AEDs', 'antiepileptic drugs'] @entity159 :: ('MESH:D013226', 'Disease') :: ['status epilepticus', 'SE']
@entity3148 :: (MESH:D004831,Disease) :: ['Dravet syndrome']
